Demostración de equivalencia terapéutica previa al análisis de minimización de costes. ¿Cuándo es legítimo utilizar el análisis de minimización de costes?

Despite its simplicity, cost-minimization analysis (CMA) is rarely used. This is because the prior statement of equal therapeutic effectiveness between the alternatives is often based on weak evidence, the reason being, in most cases, that no rejection of the null hypothesis of difference is misinterpreted as an affirmation of the nullity hypothesis. This assumption is wrong and dependent on sample size; so a cost-effectiveness analysis is preferred. However, the CMA is a legitimate option when a lack of clinical difference between the alternatives has been previously proved. The equivalence analysis based on two simultaneous one side test procedures or on a graphical representation can be used as a guide for